Novo Nordisk wins EU approval to sell Frehemgo for routine prevention of bleeding episodes in patients with hemophilia A

Observed price moves

• NVO+1.42%10 min after this headline

MoveSurge carries market-moving headlines the moment they reach the wire, each one with what the price did next.